Literature DB >> 8335514

Pharmacodynamics of antibiotics in fibrin clots.

M G Bergeron1, J Robert, D Beauchamp.   

Abstract

Fibrin is an integral component of intravascular thrombus, surgical wounds, haematomas, vegetations and foreign bodies which predispose to infection. The tropism that many pathogens have for fibrin may favour bacterial growth and lead to infection. To improve our understanding of the pharmacodynamic interaction between antibiotics and pathogens infecting fibrin clots, this review will: define the role of fibrin as a protective environment for microorganisms; give an historical perspective of in-vitro and in-vivo fibrin clots; describe the pharmacodynamic model of infected fibrin clots; review pharmacodynamic determinants of outcome; and discuss intramicrobial pharmacokinetics. Fibrin clots are hard to penetrate following antibiotic administration and there is a major gradient of concentration from the surface to the core of the clots which has great influence on bacterial growth and lysis. Resistance can develop and morphological and structural changes in bacteria may vary within the different regions of the clot.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8335514     DOI: 10.1093/jac/31.suppl_d.113

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  11 in total

Review 1.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue.

Authors:  Markus Müller; Amparo dela Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

2.  In vivo activity and pharmacodynamics of amoxicillin in combination with fosfomycin in fibrin clots infected with highly penicillin-resistant Streptococcus pneumoniae.

Authors:  P Chavanet; N Peyrard; A Pechinot; M Buisson; M Duong; C Neuwirth; A Kazmierczak; H Portier
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

3.  In vivo activity and pharmacodynamics of cefotaxime or ceftriaxone in combination with fosfomycin in fibrin clots infected with highly penicillin-resistant Streptococcus pneumoniae.

Authors:  P Chavanet; H Beloeil; A Pechinot; F Duigou; J C Buisson; M Duong; C Neuwirth; A Kazmierczak; H Portier
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

4.  Differential increased survival of staphylococci and limited ultrastructural changes in the core of infected fibrin clots after daptomycin administration.

Authors:  M J Michiels; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

5.  Influence of platelets and platelet microbicidal protein susceptibility on the fate of Staphylococcus aureus in an in vitro model of infective endocarditis.

Authors:  R C Mercier; M J Rybak; A S Bayer; M R Yeaman
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

6.  Differential distributions in tissues and efficacies of aztreonam and ceftazidime and in vivo bacterial morphological changes following treatment.

Authors:  A Turcotte; M Simard; N J Morin; D Beauchamp; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

7.  Efficacies of vancomycin, arbekacin, and gentamicin alone or in combination against methicillin-resistant Staphylococcus aureus in an in vitro infective endocarditis model.

Authors:  Dong-Gun Lee; Hye-Sun Chun; Dong-Seok Yim; Su-Mi Choi; Jung-Hyun Choi; Jin-Hong Yoo; Wan-Shik Shin; Moon-Won Kang
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

8.  Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis.

Authors:  B J McGrath; S L Kang; G W Kaatz; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

Review 9.  Human infection with Fusobacterium necrophorum (Necrobacillosis), with a focus on Lemierre's syndrome.

Authors:  Terry Riordan
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132

10.  Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin clot model.

Authors:  S L Kang; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.